1 Dec 2023 , 03:13 PM
Zydus Lifesciences experienced a 2% surge on December 1 following the US Food and Drug Administration’s final approval for a heart drug. Ivabradine, the approved drug, reduces the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure featuring reduced left ventricular ejection fraction.
Zydus Lifesciences traded at Rs 640.50 on the NSE at 3:10 pm, reflecting a 0.46% increase from the previous session’s closing price. The drug Ivabradine is also indicated for children aged 6 months and older for treating stable symptomatic heart failure due to cardiomyopathy.
The manufacturing of the drug will take place at Zydus Lifesciences’ formulation facility in Ahmedabad. The company may be eligible for 180 days of shared generic exclusivity for Ivabradine Tablets, 5 mg, and 7.5 mg, as it was among the first abbreviated new drug application (ANDA) applicants with a substantially complete ANDA featuring a paragraph IV certification for Ivabradine Tablets, 5 mg, and 7.5 mg, according to Zydus Life’s filing with the bourses.
The stock has witnessed a 52.5% gain this year, outperforming Nifty’s 11.42% rise during the same period.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.